proprietary and confidential. for alcon employees only. february 15, 2011feb. 9, 2011 retinal...

Proprietary and confidential. For Alcon employees only.

February 15, 2011Feb. 9, 2011

Retinal Disease Unmet Need and Commercial Opportunity Assessment

A proposal for Alcon Laboratories

February 15, 2011


February 15, 2011

Table of Contents

• Background and Objectives

• Our Approach, Methods and Deliverables

• Team, Timing & Fees

• IMS Consulting Qualifications

• Appendix: Bios

IMS / Alcon Retinal Disease Assessment2


February 15, 2011

Alcon seeks a comprehensive, objective view of the unmet needs and commercial opportunities across a broad array of eye-related diseases

Overall Project Goal

Alcon is seeking a comprehensive understanding of the Global Retinal/Choroidal/Vitreal Disease market and pipeline to better inform their strategic direction

•Identify unmet needs in the retinal, choroidal, and vitreal disease areas including:• Retinal and choroidal vascular diseases• Degenerative diseases of the retina• Retinal inflammatory diseases• Retinal detachment & vitreal diseases• Tumors of the retina & choroid• Inherited retinal diseases

•Identify and assess the scientific and clinical relevance of therapies, surgical interventions, and diagnostics in development

•Assess the likelihood of technical success and detail considerations that would impact the adoption of therapies into diagnosis and treatment algorithms

•Provide epidemiologic forecasts of annualized prevalence, incidence, diagnosed and treated patients by disease type by country

Background & Objectives

Research Objectives



February 15, 2011

At the highest level, retinal diseases can be grouped by etiology

The diseases Alcon are interested in can potentially fall within ten treatment algorithms

• The manifestations and management of pathologic myopia and polypoidal choroidal vasculopathy resemble those of macular degeneration

• The various stages of diabetic retinopathy have well-delineated treatment paradigms that can be described in a single comprehensive decision tree

• Branch and central vein occlusion are separate diseases, but their management can be described within a single decision tree

• Adult (melanoma) and pediatric (retinoblastoma) ocular tumors are fundamentally different, but they could potentially be described as different branches of a tumor treatment algorithm

• Given the similarity of having an underlying genetic basis and current lack of effective treatments, the various inherited retinal diseases could potentially be combined into a single treatment flow diagram

• The manifestations and management of pathologic myopia and polypoidal choroidal vasculopathy resemble those of macular degeneration

• The various stages of diabetic retinopathy have well-delineated treatment paradigms that can be described in a single comprehensive decision tree

• Branch and central vein occlusion are separate diseases, but their management can be described within a single decision tree

• Adult (melanoma) and pediatric (retinoblastoma) ocular tumors are fundamentally different, but they could potentially be described as different branches of a tumor treatment algorithm

• Given the similarity of having an underlying genetic basis and current lack of effective treatments, the various inherited retinal diseases could potentially be combined into a single treatment flow diagram

1) Macular degenerationa) Dry AMD

I) Early AMDii) Geographic AMD

b) Wet AMD

2) Pathologic myopia

3) Polypoidal choroidal vasculopathy

4) Diabetic retinal diseasea) Non-proliferative

b) Proliferative

c) Macular edema

5) Retinopathy of prematurity

6) Venous Occlusive Diseasea) Branch retinal vein occlusion

b) Central retinal vein occlusion

7) Posterior uveitis

8) Cystoid Macular Edema

9) Macular Holes

10) Retina Detachment

11) Adult ocular tumors

12) Pediatric ocular tumors

13) Retinitis pigmentosa

14) Other inherited diseases

1

3

5

7

9

2

6

8

10

4


Degenerative

Vascular

Inflammatory

Mechanical

Neoplastic

Hereditary



February 15, 2011

IMS successfully supported Alcon in a very similar effort for the glaucoma franchise in 2009 / 2010

• IMS worked with the Alcon team over 2.5 months to develop an objective assessment of the glaucoma space

• The Alcon / IMS team collaborated throughout the project, with phased deliverables and checkpoints

• IMS brought to bear a broad team of both functional (Pricing, Reimbursement, Market Access, Strategy) and therapeutic expertise to maximize the insights to the Alcon team




February 15, 2011

Based on initial discussions and RFP, Alcon seeks objective views in three key areas

Unmet needs analysis:What are the unmet needs for

patients?

Clinical and technical assessment:

What future treatment modalities hold the highest

promise?

Commercial assessment:What commercially viable

opportunities exist?

• What are the unmet medical needs of patients?

• Of those unmet needs, would solutions / treatments of them present true clinical advances/ benefits?

What strategic alternatives should Alcon consider to compete in the retinal/ choroidal/ vitreal disease marketplace?

• Based on EPI forecasts, what disease areas represent sizable market opportunities to pursue?

• What approaches may represent commercially viable (reimbursable) advancements on current therapies?

• What relevant therapies (pharma, device, surgical, diagnostics) are under development and do they represent significant treatment advancements?

• What is the likelihood of technical/ clinical success of these different treatment pathways?

• KOL perspectives on treatment evolution

• Testing of treatment alternatives with a mix of specialist physicians

• Literature and secondary market information research

• IMS, Alcon and third party epidemiological data and forecasts

• Conversations with leading academics / epidemiologists focused on diseases of the eye

• Literature and secondary research• IMS forecasting, EPI and pricing and

market access functional expertise

• Secondary research profiling competing treatment platforms

• KOL and physician primary research (qual and quant)

• IMS therapeutic area expertise and input

Key Questions:

Supporting Information:




February 15, 2011

Table of Contents

• Background and Objectives

• Our Approach, Methods and Deliverables

• Team, Timing & Fees

• IMS Consulting Qualifications

• Appendix: Bios



February 15, 2011

There are several important skills required to ensure success of this project

Skills Required for Success IMS Consulting Team’s Skills & Experience

Extensive consulting expertise in the pharmaceutical industry

• Focused exclusively on serving the pharmaceutical, biotech and device industry

• We have the ability to translate findings and insights into tangible, actionable, and relevant recommendations

Deep understanding of the ophthalmic space

• IMS has worked on a variety of ophthalmic projects in all major markets

• Extensive experience in ophthalmic-specific P&MA, clinical and competitive issues

Experience with Alcon conducting landscape studies

• IMS recently and successfully executed similar work with Alcon’s glaucoma franchise

Global presence in all 11 countries

• Over 1,700 consultants based in some 30 countries

Deep functional expertise

• We have significant experience conducting projects that inform strategy through evidence-based decision-making, leaning on our functional expertise in pricing and market access, risk assessment, and valuation modeling

IMS Consulting Qualifications



February 15, 2011

CorporatePortfolio

IMS Strategy & Portfolio Analysis We work at three levels of client problems, focusing to a varying extent on organic and/or externally-sourced options

Asset Portfolio &Franchise Strategy

Product Strategy & Valuation

Development Strategy

Market Assessment & Forecasting

Resource Allocation

R&D Productivity

Business Model Design

Strategic Footprint & Direction

M&A Strategy

Post Merger Portfolio Integration

Product Licensing

Deal valuation

Therapy Area Expansion

Geographic Expansion

Organic Choices

Externally-focused options

IMS Consulting Qualifications Consulting Expertise



February 15, 2011

Our consulting team excels at business intelligence, valuation, and strategy

• Assessing difficult-to-value assets with uncertain future prospects… molecules, brands, franchises, businesses, etc.

• Obtaining important business intelligence that will provide context for decision-making

• Helping organizations reach agreement on difficult choices involving many conflicting views…project teams, executive committees, boards of directors, etc.

• Managing decision processes that incorporate multiple different alternatives or options…strategies, investments, acquisitions, etc.

• Managing a portfolio brings these capabilities together:

– Gaining clarity on a complex mix of decisions

– Where there are many possible options, valuation is based on uncertain future prospects, and there are many conflicting views

IMS Consulting Qualifications Consulting Expertise



February 15, 2011

IMS Consulting has deep expertise in the area of eye diseases and care

Project Geographies Description

Competitive Analysis for Ophthalmic Portfolio

US & EU 5 Undertake a market and portfolio valuation for a range of new ophthalmic products (areas include glaucoma, dry eye syndrome, AMD, diabetic neurapathy, etc) to create a platform for franchise growth.

Market Potential for New Technology to Treat Detached Retina

US, EU5, and Australia

Valued a potential acquisition target for detached retina using assessment of alternate technologies and impact on P&R. Recommended strategy via a high-level forecast model

P&R strategy for a new wet AMD compound

EU 5 Understand competitive dynamics in wet AMD and P&R impact on a new compound’s value proposition to launch in EU.

Optimize access for current ophthalmology product

EU 5 Develop value messages to influence payer decision-making process; quantify impact of scenario-based value messages on product access and uptake

Market Potential for Uveitis and Diabetic Macular Edema

US Analyzed size and treatment flow for Uveitis via physician and patient research to build 5 year forecast model. Conceptualized potential for Diabetic Macular Edema using Uveitis intelligence.

Achieving optimal reimbursement for a macular degeneration product

EU 5 Developed a strategic reimbursement launch plan to ensure maximum coverage and reimbursement for a macular degeneration product

Preparing for market access for a new PGE inhibitor

US Analyze a product's clinical profile and provide guidance as to price potential and phase III clinical trial design activities to undertake to support the price & value

Market and ophthalmology pipeline evaluation

5 EU Mkts Assessed the ophthalmology markets for glaucoma, AMD, diabetic retinopathy, dry eye, and potential for a company’s pipeline

Examples are illustrative, not exhaustive

IMS Consulting Qualifications Ophthalmic Experience



February 15, 2011

IMS successfully supported Alcon in a very similar effort for the glaucoma franchise in 2009 / 2010

Strategic Unmet Needs and Assessment of Portfolio Growth Options in Glaucoma

Glaucoma Patient Model

J anuary 2010

Experience with Alcon

• IMS worked with the Alcon team over 2.5 months to develop an objective assessment of the glaucoma space

• The Alcon / IMS team collaborated throughout the project, with phased deliverables and checkpoints

• IMS brought to bear a broad team of both functional (Pricing, Reimbursement, Market Access, Strategy) and therapeutic expertise to maximize the insights to the Alcon team

Strategic Unmet Needs and Assessment of Portfolio Growth Options in Glaucoma

Final Presentation: Growth Opportunities

J anuary 25, 2010




February 15, 2011

IMS Management Consulting is the largest consulting firm dedicated to the life sciences industry


We have a presence in ~30 countries

including the 11 scoped in this project

We have a presence in ~30 countries

including the 11 scoped in this project

Global Presence



February 15, 2011

Our specialist consultancy business model provides depth in critical issue areas

Product and Portfolio Strategy

Commercial Effectiveness

Pricing and Market Access

Strategy & Portfolio Analysis

―Forecasting & Valuation

―Licensing & Acquisitions

―Portfolio Management

―Strategy

Competitive intelligence

Precision Sales Force TM

Promo.360 TM

Performance Mgt studies and dashboards

Primary market research

Learning solutions

Pricing and reimbursement

Health economics and outcomes research

Core

O

fferi

ng

s

IMS Consulting Qualifications Functional Expertise


proprietary and confidential. for alcon employees only. february 15, 2011feb. 9, 2011 retinal...

Documents

diseases alcon

alcon employees

separate diseases

alcon laboratories

retinal disease unmet

treatment algorithms

single treatment flow

disease type